Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19736953 | 0.79 | ENPP2 (0.43) | SUV39H2ENPP2HTR1DAAK1DYRK1A | |
| SCHEMBL19736954 | 0.73 | MAPT (0.36) | SUV39H2PIK3CA | |
| SCHEMBL14745402 | 0.72 | RAB9A (0.44) | PIK3CG | |
| SCHEMBL21014272 | 0.72 | KDM4E (0.50) | PIK3CDPIK3CA | |
| SCHEMBL21033469 | 0.71 | ENPP2 (0.39) | SUV39H2ENPP2HTR1DAAK1PIK3CD | |
| SCHEMBL19736843 | 0.71 | ATR (0.44) | — | |
| SCHEMBL19736862 | 0.70 | PIK3CD (0.32) | SUV39H2PIK3CDPIK3CAPIK3R1PIK3CB | |
| SCHEMBL21033161 | 0.70 | PTGS1 (0.43) | SUV39H2ENPP2PIK3CDPIK3CADYRK1A | |
| SCHEMBL19736614 | 0.69 | PIK3CD (0.46) | ENPP2AAK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL21078724 | 0.69 | PIK3CD (0.31) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-19 | — | — | US | disclosed |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-06 | — | — | US | disclosed |
| WO-2017216292-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | PIK3CA, PIK3CD, PIK3CB | SUV39H2 2093/4885ENPP2 2156/4885HTR1D 2063/4885 |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | SUV39H2 2093/4885ENPP2 2156/4885HTR1D 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.